NCT05932914
Liver Biopsy Following Gene Therapy For Hemophilia
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 30 versions: 29 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Start date pushed from Oct 2026 to Nov 2026
- Notable Eligibility criteria expanded, about 12 words
- Start date: Sep 2026 to Oct 2026
- Secondary endpoints: details revised at 1 of 5 entries
- Site details revised
- Minor Start date: Aug 2026 to Sep 2026v28
- Minor Start date: Jul 2026 to Aug 2026v27
- Minor Start date: Jun 2026 to Jul 2026v26
Show 23 earlier versionsHide 23 earlier versions
- Minor Start date: May 2026 to Jun 2026
- Site contact updated
- Notable Start date: Mar 2026 to May 2026v24
- Minor Start date: Feb 2026 to Mar 2026v23
- Minor Start date: Jan 2026 to Feb 2026v22
- Notable Start date: Nov 2025 to Jan 2026v21
- Minor Start date: Oct 2025 to Nov 2025v20
Notable Primary and study completion dates: May 2026 to Jan 2030v19 Show 4 more changesShow less
- Start date: Aug 2025 to Oct 2025
- Eligibility criteria expanded, about 28 words
- Study description expanded, about 28 words
- Collaborators expanded, about 3 words
- Notable Start date: May 2025 to Aug 2025v18
- Notable Primary and study completion dates: May 2025 to May 2026
- Start date: Mar 2025 to May 2025
- Minor Start date: Jan 2025 to Mar 2025v16
- Notable Start date: Oct 2024 to Jan 2025v15
- Notable Start date: Jul 2024 to Oct 2024v14
- Minor Start date: Jun 2024 to Jul 2024v13
- Minor Start date: May 2024 to Jun 2024v12
- Minor Start date: Apr 2024 to May 2024v11
- Minor Start date: Mar 2024 to Apr 2024v10
- Minor Start date: Feb 2024 to Mar 2024v9
- Minor Start date: Jan 2024 to Feb 2024v8
- Minor Start date: Dec 2023 to Jan 2024v7
- Minor Start date: Nov 2023 to Dec 2023v6
- Minor Start date: Oct 2023 to Nov 2023v4
- Minor Start date: Sep 2023 to Oct 2023v3
- Notable Start date: Jul 2023 to Sep 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Assessment of the number of hepatocytes transduced with AAV vector genome in liver biopsy samples analyzed by FISH
Timeframe: single time point (day of biopsy)
Secondary (5)
The degree of hepatocyte damage at a morphological level
The number and type of hot spots for integration of AAV provirus in liver cells
The number of hepatocytes revealing FVIII/FIX RNA in-situ transcripts
The number and types of epigenetic changes within the AAV genome in the liver
The qualitative and quantitative assessment of the RNA transcriptome
Arms and interventions
Participants
Those who meet the Eligibility Criteria
Procedures: Liver Biopsy
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States